GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Shiller PE Ratio

Phio Pharmaceuticals (FRA:44R3) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Phio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Shiller PE Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Phio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Shiller PE Ratio falls into.



Phio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Phio Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Phio Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Phio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -10,529.731 100.560 -13,798.477
201409 -7,047.050 100.428 -9,246.777
201412 -6,736.417 99.070 -8,960.352
201503 -6,114.422 99.621 -8,087.998
201506 -1,983.019 100.684 -2,595.397
201509 -2,260.102 100.392 -2,966.662
201512 -2,425.742 99.792 -3,203.200
201603 -2,023.679 100.470 -2,654.242
201606 -1,988.563 101.688 -2,576.951
201609 -1,972.861 101.861 -2,552.264
201612 -3,754.042 101.863 -4,856.472
201703 -1,635.296 102.862 -2,094.969
201706 -657.882 103.349 -838.838
201709 -581.421 104.136 -735.747
201712 -468.463 104.011 -593.516
201803 -481.729 105.290 -602.913
201806 -259.879 106.317 -322.112
201809 -192.309 106.507 -237.936
201812 -58.013 105.998 -72.122
201903 -60.640 107.251 -74.507
201906 -49.064 108.070 -59.827
201909 -49.359 108.329 -60.042
201912 -50.702 108.420 -61.624
202003 -14.444 108.902 -17.478
202006 -3.623 108.767 -4.389
202009 -4.075 109.815 -4.890
202012 -4.044 109.897 -4.849
202103 -3.226 111.754 -3.804
202106 -1.992 114.631 -2.290
202109 -2.856 115.734 -3.252
202112 -2.713 117.630 -3.039
202203 -2.125 121.301 -2.309
202206 -2.100 125.017 -2.214
202209 -3.171 125.227 -3.337
202212 -2.262 125.222 -2.380
202303 -2.942 127.348 -3.044
202306 -1.357 128.729 -1.389
202309 -1.068 129.860 -1.084
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals  (FRA:44R3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Phio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (FRA:44R3) Business Description

Traded in Other Exchanges
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines